World Health Organization Classification^a

• AML with t(8;21)(q22;q22);RUNX1/RUNX1T1^b
• AML with abnormal bone marrow eosinophils [inv(16)(p13q22) or t(16;16)(p13;q22);CBFβ/MYH11]^b
• Acute promyelocytic leukemia [AML with t(15;17)(q22;q12) (PML/RARα) and variants]^b
• AML with 11q23 (MLL) abnormalities

• Following a myelodysplastic syndrome or myelodysplastic syndrome/ myeloproliferative disorder
• Without antecedent myelodysplastic syndrome

III. AML and myelodysplastic syndromes, therapy-related

• Alkylating agent-related

• Topoisomerase type II inhibitor-related
• Other types

IV. AML not otherwise categorized

• AML minimally differentiated

• AML without maturation
• AML with maturation
• Acute myelomonocytic leukemia
• Acute monoblastic and monocytic leukemia
• Acute erythroid leukemia
• Acute megakaryoblastic leukemia
• Acute basophilic leukemia
• Acute panmyelosis with myelofibrosis
• Myeloid sarcoma

French-American-British (FAB) Classification^c

Incidence

M0: Minimally differentiated leukemia

5%

M1: Myeloblastic leukemia without maturation

20%

M2: Myeloblastic leukemia with maturation

30%

M3: Hypergranular promyelocytic leukemia

10%

M4: Myelomonocytic leukemia
M4Eo: Variant: Increase in abnormal marrow eosinophils

20%

M5: Monocytic leukemia

10%

M6: Erythroleukemia (DiGuglielmo’s disease)

4%

M7: Megakaryoblastic leukemia

1%